BioCentury | Sep 14, 2018
Preclinical News

UCSD researchers identify mechanism, target in NASH

...in Phase II testing for NASH. Caspases control the cleavage and activation of sterol regulatory element binding transcription factor 1 (SREBF1; SREBP1...
...and other nutrients are converted into fatty acids, triglycerides and cholesterol in the liver. Uncontrolled SREBF1/2...
...found in NASH. However, the mechanism by which caspases induce this expression was unknown, as SREBF1...
BioCentury | Jul 12, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2018

New Therapeutic Targets and Biomarkers: June 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jun 13, 2018
Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Hypercholesterolemia Patient sample and mouse studies suggest inhibiting LIMA1 could help treat hypercholesterolemia. Whole-genome sequencing of patient plasma samples identified an association between a rare frameshift variant of LIMA1 and low levels of LDL-C...
BioCentury | Jun 7, 2018
Preclinical News

Inhibiting LIMA1 could treat hypercholesterolemia

A study published in Science from researchers at the Chinese Academy of Sciences suggested that inhibiting LIM domain and actin binding 1 (LIMA1; SREBP3) could reduce cholesterol absorption and help treat hypercholesterolemia. High levels of...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Cancer

INDICATION: Cancer; colorectal cancer; cutaneous T cell lymphoma (CTCL) In vitro and cell culture studies identified agonists of RXR heterodimerization that could help treat colorectal cancer, CTCL and other cancers without causing the metabolic and...
BioCentury | Jun 27, 2016
Clinical News

CAT-2054: Phase IIa data

Top-line data from a double-blind, U.S. Phase IIa trial in 153 patients with hypercholesterolemia showed that oral CAT-2054 plus atorvastatin missed the primary endpoint of reducing LDL-C from baseline to week 4 vs. placebo plus...
BioCentury | Jan 18, 2016
Clinical News

CAT-2054: Phase IIa started

Catabasis began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 250 and 400 mg oral CAT-2054 once or twice daily with 40 mg oral atorvastatin daily for 4 weeks in about 150 patients. Catabasis...
BioCentury | Jun 9, 2011
Targets & Mechanisms

Nuclear receptor in the crosshairs of diabetes

...and improved glucose homeostasis compared with vehicle control. DLPC also decreased expression of sterol regulatory element binding transcription factor 1 (Srebf1; Srebp1...
...member 2 (NR5A2; LRH-1), which according to the model would suppress sterol regulatory element binding transcription factor 1 ( SREBF1 ; SREBP1...
...serum insulin levels and will thus further reduce SREBP1 activity (purple arrows).In the current model, SREBP1...
BioCentury | Feb 3, 2011
Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Cardiomyopathy; dyslipidemia Sterol regulatory element binding protein (SREBP) Drosophila studies suggest that inhibiting SREBP could help treat dyslipidemia-related cardiomyopathy. In Drosophila...
BioCentury | Jan 27, 2011
Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Diabetes; obesity; atherosclerosis Sterol regulatory element binding protein (SREBP) In vitro and mouse studies suggest that inhibiting SREBP could help treat obesity, type 2 diabetes...
Items per page:
1 - 10 of 17